- Case report
- Open Access
- Open Peer Review
Nuclear protein in testis carcinoma of the mediastinum: a case report
© The Author(s). 2017
- Received: 13 January 2017
- Accepted: 22 May 2017
- Published: 9 June 2017
Nuclear protein in testis carcinoma is a rare and very aggressive undifferentiated cancer which characteristically arises in the midline of the head, neck, and mediastinum.
We describe the case of a 46-year-old white woman admitted for superior vena cava syndrome revealing a mediastinal tumor. Pathological examination of specimens obtained by mediastinoscopy revealed an undifferentiated tumor with solid growth and positive immunoreactivity for p40 and negative immunoreactivity for cytokeratin markers. Immunohistochemical staining was positive for nuclear protein in testis, allowing the diagnosis of nuclear protein in testis midline carcinoma of the mediastinum.
We present a rare case of mediastinal nuclear protein in testis carcinoma with diagnosis based on nuclear protein in testis protein positivity and atypical immunohistochemical features including p40 positivity and anti-cytokeratin negativity. Physicians must remain aware of the possibility of nuclear protein in testis carcinoma especially in young patients with thoracic symptoms and suspicion of neoplasm.
- NUT carcinoma
- Superior vena cava syndrome
- Mediastinal neoplasms
Nuclear protein in testis (NUT) carcinoma is a rare and very aggressive undifferentiated cancer, which characteristically arises in the midline of the head, neck, and mediastinum  and shows aggressive behavior with early locoregional invasion and distant metastases . Its incidence is unknown and it occurs mainly in adolescents and young adults . Because of the rarity of this condition, no consensus has been reached concerning the optimal treatment strategy. The prognosis remains extremely poor with a 6.7-month median survival and a global survival of 19% within the first 2 years after diagnosis . The pathophysiology involves a rearrangement of the NUT gene on chromosome 15q14 with members of the BRD gene family (BRD4 and BRD3) resulting in a BRD–NUT fusion product, which decreases histone acetylation and therefore suppresses squamous cell differentiation [4, 5]. Pathological examination may reveal positivity for cytokeratins (CKs) and p63, a squamous basal cell marker, leading to the incorrect diagnosis of squamous cell carcinoma . We report a case of superior vena cava syndrome revealing a NUT carcinoma of the mediastinum.
After multidisciplinary cancer team meeting discussions, our patient underwent a course of radiation therapy to her chest (20 Gy in five fractions) and received three cycles of carboplatin and paclitaxel. Her symptoms of vena cava syndrome improved and a chest CT scan showed that the size of the mediastinal mass had decreased by 32%: a partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria . After the fourth cycle of chemotherapy, she developed severe peripheral neuropathy to paclitaxel leading to discontinuation of treatment. One month after discontinuation of chemotherapy, she developed recurrence of vena cava syndrome symptoms and a chest CT scan showed mediastinal progression of the thoracic mass. Due to her poor general state and despite second-line chemotherapy with carboplatin and pemetrexed, she rapidly progressed to the point of palliative care and died 6 months after the initial diagnosis.
NUT carcinoma is a rare carcinoma with only 39 cases of intrathoracic tumors published to date [3, 8]. Chronic cough, dyspnea, hemoptysis, chest pain, and fatigue are among the main presenting complaints .
Histological findings typically show two types of tumor cell populations: (1) poorly differentiated carcinoma, and (2) well-differentiated squamous cell islands with focal keratinization [3, 6]. Positive immunoreactivity to anti-CK antibodies AE1/AE3, as well as EMA (a marker for the epithelial nature of neoplastic cells), p63, and p40 (markers of squamous and basal cell carcinomas) are the usual immunohistochemical findings and should raise the suspicion of NUT carcinoma in young individuals with a midline tumor . The differential diagnosis of mediastinal NUT carcinomas includes undifferentiated malignancies including high-grade hematologic malignancies, endocrine carcinomas, and primitive neuroectodermal tumor . In the case of negative anti-CK antibodies, Ewing sarcoma and small round cell tumors must be ruled out because they are difficult to discriminate morphologically from NUT carcinoma .
In our case, immunohistochemistry revealed positivity for p40 and negativity for CK. To the best of our knowledge, our patient is the third reported case of intrathoracic NUT carcinoma with positivity for p40 .
Nuclear positivity of more than 50% for anti-NUT antibody with fluorescence in situ hybridization (FISH) analysis allows the diagnosis of NUT carcinoma with 100% specificity . Characterization of both fusion genes BRD4–NUT and BRD3–NUT, and more rarely NSD3–NUT, is not mandatory for the diagnosis, but is recommended for its possible association with unique prognostic features . NUT carcinomas lacking BRD4 fusion gene rearrangements are more differentiated and therefore possibly less aggressive . Fusion gene translocation assessment was not performed in our patient.
At present, there is no consensus concerning the optimal treatment strategy. A combination of multidrug chemotherapy with gemcitabine, docetaxel, and cisplatin and locoregional radiation therapy achieved complete response in a case of NUT midline carcinoma . Administration of histone deacetylase inhibitors such as vorinostat is a promising therapeutic concept, with limitations due to severe side effects . Bromodomain (BRD) and extra-terminal proteins (BET) inhibitors showed rapid antitumor activity in three patients with BRD4–NUT fusion NUT carcinoma .
We present a rare case of mediastinal NUT carcinoma revealed by superior vena cava obstruction with a definitive diagnosis based on NUT protein positivity and atypical immunohistochemical features including p40 positivity and anti-CK negativity.
We have received no funding.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
GB, GD, and JV-B contributed to the literature search, study design, and writing of the manuscript. PB contributed to histological examination of the specimens and writing of the manuscript. EU-C contributed to immunohistochemical staining with NUT antibody and performed critical review of the manuscript. CL, SD, J-MP, and HV contributed to the patient’s treatment and follow-up and performed a critical review of the manuscript for important intellectual content. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
The authors have no ethical conflicts to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Mills AF, Lanfranchi M, Wein RO, Mukand-Cerro I, Pilichowska M, Cowan J, et al. NUT midline carcinoma: a case report with a novel translocation and review of the literature. Head Neck Pathol. 2014;8(2):182–6.View ArticlePubMedGoogle Scholar
- Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Lüer SC, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18(20):5773–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Harms A, Herpel E, Pfarr N, Penzel R, Heussel C-P, Herth FJF, et al. NUT carcinoma of the thorax: case report and review of the literature. Lung Cancer Amst Neth. 2015;90(3):484–91.View ArticleGoogle Scholar
- French CA. Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol. 2010;63(6):492–6.View ArticlePubMedGoogle Scholar
- Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010;29(17):2943–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Nakamura H, Tsuta K, Tsuda H, Katsuya Y, Naka G, Iizuka T, et al. NUT midline carcinoma of the mediastinum showing two types of poorly differentiated tumor cells: a case report and a literature review. Pathol Res Pract. 2015;211(1):92–8.View ArticlePubMedGoogle Scholar
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990. 2009;45(2):228–47.Google Scholar
- Samples S, Gleditsch K, Polimenakos A. Intrapericardial NUT midline carcinoma: unusual presentation of a rare tumor and literature review with management considerations. Pediatr Cardiol. 2016;37(1):208–11.View ArticlePubMedGoogle Scholar
- Stelow EB. A review of NUT midline carcinoma. Head Neck Pathol. 2011;5(1):31–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Haack H, Johnson LA, Fry CJ, Crosby K, Polakiewicz RD, Stelow EB, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009;33(7):984–91.View ArticlePubMedPubMed CentralGoogle Scholar
- Ueki H, Maeda N, Sekimizu M, Yamashita Y, Moritani S, Horibe K. A case of NUT midline carcinoma with complete response to gemcitabine following cisplatin and docetaxel. J Pediatr Hematol Oncol. 2014;36(8):e476–80.View ArticlePubMedGoogle Scholar
- Maher OM, Christensen AM, Yedururi S, Bell D, Tarek N. Histone deacetylase inhibitor for NUT midline carcinoma. Pediatr Blood Cancer. 2015;62(4):715–7.View ArticlePubMedGoogle Scholar
- Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord J-P, de LM Rouge T, et al. Clinical response of carcinomas harboring the BRD4–NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 2016;6(5):492–500.View ArticlePubMedPubMed CentralGoogle Scholar